CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 370 target
Drug / intervention
Plasma EBV DNA qPCR testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05037357
NCT05037357N/AUnknown
CompareCT.gov

Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements at Multiple Centers in NPC Epidemic Regions

Sun Yat-sen University·observational·Posted Sep 8, 2021·Updated Jul 6, 2022

In Brief

An observational study evaluating Plasma EBV DNA qPCR test for Nasopharyngeal Carcinoma. Targeting 370 participants across 1 site.

Detailed Summary

Plasma Epstein-Barr virus (EBV) DNA will be measured in native plasma samples of nasopharyngeal carcinoma (NPC) patients, respectively, by three medical centers and a qualified laboratory in Southern China, the highest endemic area of NPC. Passing-Bablok regression and difference plots will be used to compare results from each center to the all-method median and mean values. Agreement among methods will be evaluated against bias derived from a biological variation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
CollaboratorsWuzhou Red Cross Hospital, Zhongshan People's Hospital, Guangdong, China

Timeline

N/AUnknownOverdue
20222023202420252026
First PostedSep 8, 2021
Enrollment StartAug 1, 2021
Primary CompletionDec 1, 2022
Study CompletionJun 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 4.8 years ago

Interventions

Plasma EBV DNA qPCR testother

Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.